Photodynamic therapy for intergluteal warts in a child affected by Rett syndrome

Pomi, Federica Li; Macca, Laura; Peterle, Lucia; Romeo, Paola; Vaccaro, Mario; Borgia, Francesco

doi:10.1016/j.pdpdt.2023.103620

Cited by 5 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After a predetermined incubation period and upon irradiation with red light (~630 nm), these prodrugs stimulate cytotoxic reactive oxygen species (ROS) production, selectively destroying cells with a high metabolic state, including infective, tumoral, and inflammatory ones [31]. PDT has been used successfully in the treatment of non-melanoma skin cancer and actinic keratoses, with growing experience in the management of infectious dermatoses; however, less evidence exists for the treatment of inflammatory diseases, including NL [59][60][61][62][63]. The literature shows variable results about the efficacy of PDT, with clearance rates that are often very different from each other, with great variability between the number of sessions and the interval between sessions.…”

Section: Discussionmentioning

confidence: 99%

Shedding Light on Photodynamic Therapy in the Treatment of Necrobiosis Lipoidica: A Multicenter Real-Life Experience

Li Pomi,

Motolese,

Paganelli

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

Necrobiosis Lipoidica (NL) is a dermatological condition characterized by the development of granulomatous inflammation leading to the degeneration of collagen and subsequent formation of yellowish-brown telangiectatic plaques usually localized on the pretibial skin of middle-aged females. Due to its rarity and unclear etiopathogenesis, therapeutic options for NL are not well-standardized. Among them, photodynamic therapy (PDT) is an emerging tool, although its efficacy has primarily been evaluated in single case reports or small case series. This study reports the real-life experience of a cohort of NL patients treated with PDT at the Section of Dermatology of the University Hospital of Messina and Reggio-Emilia. From 2013 to 2023, 17 patients were enrolled —5 males (29%) and 12 females (71%) aged between 16 and 56 years (mean age: 42 ± 13 years), with a median duration of NL of 8 years. The overall complete clearance (>75% lesion reduction) was 29%, while the partial clearance (25–75% lesion reduction) was 59%, with 12% being non-responders. This study adds to the little amount of evidence present in the literature regarding the effectiveness of PDT in the treatment of NL. Variability in treatment responses among patients underscores the need for personalized protocols, optimizing photosensitizers, light sources, and dosimetry. The standardization of treatment protocols and consensus guidelines are essential to ensure reproducibility and comparability across studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Shedding Light on Photodynamic Therapy in the Treatment of Necrobiosis Lipoidica: A Multicenter Real-Life Experience

Li Pomi,

Motolese,

Paganelli

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…PDT is a field-therapy, non-invasive photochemotherapeutic procedure based on the topical application of 5-aminolaevulinic acid (ALA) or its methylated ester (MAL), two lightresponsive prodrugs, which, after irradiation with a red light of ~630nm, stimulate cytotoxic reactive oxygen species, causing selective destruction of cells with a high metabolic state, including cancerous and pre-cancerous ones [26,27]. Pooled data from three studies on up to two ALA-red light PDT treatments showed rates of baseline lesion clearance of 89.1% and 32.7% at twelve weeks post-treatment for ALA-PDT and placebo-PDT patients, respectively [28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study

Li Pomi,

Vaccaro,

Pallio

et al. 2024

Medicina

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Tirbanibulin 1% ointment is a novel synthetic anti-proliferative agent that inhibits tubulin polymerization. It is approved for treating actinic keratosis (AK) on the face and scalp in adults. It has demonstrated good efficacy, an adequate safety profile and excellent patient adherence in the phase 3 clinical trials, however data about its real-life efficacy and safety are lacking. Here we report the experience of the dermatology unit of the University Hospital of Messina. Materials and Methods: We performed a spontaneous open-label, prospective non-randomized study to assess the effectiveness and safety of tirbanibulin 1% ointment for the treatment of 228 AKs in 38 consecutive patients—28 males (73%) and 10 females (26%)—aged between 52 and 92 years (mean age: 72 ± 8.92 years). Results: Total clearance was recorded in 51% of lesions, while partial clearance was recorded in 73% of lesions. An excellent tolerability profile and high compliance rate were observed, with no treatment discontinuation due to the onset of adverse events. Conclusion: Our real-life experience confirms the effectiveness and safety of tirbanibulin ointment for the treatment of AKs.

show abstract

Anti-aging Effects of Tirbanibulin 1% Ointment: A Real-Life Experience

Li Pomi,

Peterle,

d’Aloja

et al. 2024

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction Tirbanibulin 1% ointment has been licensed to treat non-hyperkeratotic actinic keratosis (AKs) on the face and scalp in adults to ensure excellent patient tolerability due to the mild side effects and the brief application time compared to other topical therapies on the market. A growing body of evidence suggests that, beyond their primary function, the treatments for AKs and the cancerization field may inadvertently confer substantial cosmetic benefits to patients. Methods We report a single-center retrospective case series of patients referred to the Dermatology Unit of the University Hospital of Messina, Italy, between February and December 2023 seeking treatment for AKs in the context of photodamaged areas in which the application of tirbanibulin 1% ointment induced, besides clearance of AKs, anti-aging effects on both skin texture and solar lentigos. Results Seven patients affected by Olsen grade 1–2 AKs experienced a powerful rejuvenating effect in the treated areas, with a marked efficacy in skin lightening and clearance of solar lentigo. Conclusions Tirbanibulin 1% ointment seems able to improve skin aging as a desirable side effect at the site of application for AKs on chronic photodamaged skin. Such preliminary observation needs further confirmation in real-life studies on larger cohorts of patients, to explain the pathogenic mechanisms responsible for such aesthetically relevant results.

show abstract

Photodynamic therapy for intergluteal warts in a child affected by Rett syndrome

Cited by 5 publications

References 11 publications

Shedding Light on Photodynamic Therapy in the Treatment of Necrobiosis Lipoidica: A Multicenter Real-Life Experience

Shedding Light on Photodynamic Therapy in the Treatment of Necrobiosis Lipoidica: A Multicenter Real-Life Experience

Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study

Anti-aging Effects of Tirbanibulin 1% Ointment: A Real-Life Experience

Contact Info

Product

Resources

About